Drug Information

Drug General Information
Drug ID
D0I8QS
Former ID
DNC000339
Drug Name
BN82451
Drug Type
Small molecular drug
Indication Parkinson's disease [ICD9: 332; ICD10:G20] Phase 2 [524900]
Company
Ipsen
Structure
Download
2D MOL

3D MOL
Formula
C18H26N2OS
Canonical SMILES
CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CSC(=N2)CN
InChI
1S/C18H26N2OS/c1-17(2,3)12-7-11(14-10-22-15(9-19)20-14)8-13(16(12)21)18(4,5)6/h7-8,10,21H,9,19H2,1-6H3
InChIKey
HAQOEWGSBVQDHB-UHFFFAOYSA-N
PubChem Compound ID
9905090
PubChem Substance ID
14874629, 24186764, 45976758, 79552524, 134224185, 134339785, 172649977, 172914359, 198986583, 226555440, 249026717
Target and Pathway
Target(s) Sodium channel Target Info Blocker [537349]
Cyclooxygenase Target Info Inhibitor [537349]
KEGG Pathway Dopaminergic synapse
Reactome Interaction between L1 and Ankyrins
References
Ref 524900ClinicalTrials.gov (NCT02231580) Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients. U.S. National Institutes of Health.
Ref 537349Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.